Stocktoria
Trevi Therapeutics, Inc. TRVI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-05-07
Trevi Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $33.5M | $39.4M | $23.7M | $19.8M | $23.0M |
| Operating income | -$49.3M | -$51.5M | -$33.9M | -$29.9M | -$32.5M |
| Interest expense | — | — | $391,000 | $1.2M | $1.2M |
| Income tax | -$64,000 | -$30,000 | -$32,000 | -$36,000 | -$21,000 |
| Net income | -$42.8M | -$47.9M | -$29.1M | -$29.2M | -$33.9M |
| EPS (diluted) | $-0.32 | $-0.47 | $-0.29 | $-0.45 | $-1.49 |
| Operating cash flow | -$42.1M | -$38.3M | -$31.7M | -$28.2M | -$28.9M |
| Free cash flow | -$42.1M | -$38.3M | -$31.8M | -$28.3M | — |
| Cash & equivalents | $18.9M | $34.1M | $32.4M | $12.6M | $36.8M |
| Total assets | $193.4M | $110.9M | $89.4M | $123.0M | $38.5M |
| Total liabilities | $10.2M | $11.3M | $6.9M | $15.6M | $21.4M |
| Shareholders' equity | $183.2M | $99.6M | $82.5M | $107.5M | $17.1M |
Source: SEC EDGAR filings · CIK 0001563880 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.